Yes, there is an FDA-approved bird flu vaccine for humans, and additional next-generation versions are in late-stage clinical trials. However, the approved vaccine is not available at your local pharmacy. It exists primarily as a preparedness tool, stockpiled by the federal government and reserved for people at increased risk of exposure or for rapid deployment if H5N1 ever triggers a pandemic.
The Approved Vaccine: Audenz
The only currently licensed H5N1 vaccine in the United States is called Audenz, manufactured by Seqirus. The FDA approved it on January 31, 2020, for people six months and older who are at increased risk of exposure to the H5N1 virus. That means it’s intended for groups like poultry workers, laboratory personnel, and emergency responders rather than the general public.
Audenz is an inactivated vaccine, meaning it contains killed virus rather than live virus. It also includes an adjuvant, a substance that boosts the immune response, which is important because H5N1 viruses don’t naturally provoke a strong antibody response the way seasonal flu strains do. In clinical trials covering roughly 9,600 participants across 13 studies, no serious vaccine-related side effects were reported.
What the U.S. Has Stockpiled
The U.S. Strategic National Stockpile holds doses of H5N1 vaccine specifically for pandemic preparedness. The Department of Health and Human Services has moved forward with plans to produce 4.8 million additional doses, and federal officials have confirmed that one of two candidate vaccine viruses in the stockpile is a good match to the H5N1 strain currently circulating in birds and cattle.
That match question matters. The stockpiled vaccines were originally designed to target H5N1 strains from the early 2000s, which came from Indonesia and Vietnam. The strain now spreading belongs to a different genetic group called clade 2.3.4.4b. An FDA-led study tested blood samples from 68 adults who had received the older stockpiled vaccines and found that the adjuvanted versions still generated antibodies capable of neutralizing the current clade. That’s encouraging: it means existing stockpiled vaccines could serve as a bridge while updated versions are produced, rather than being useless against today’s virus.
mRNA Vaccines in Development
Moderna is testing an mRNA-based H5N1 vaccine called mRNA-1018, built on the same platform as its COVID-19 shot. This vaccine is now in a Phase 3 trial, the final stage before potential approval, enrolling around 4,000 adults across the United Kingdom and the United States. The Coalition for Epidemic Preparedness Innovations (CEPI) is funding the effort with up to $54.3 million to help advance the vaccine through licensure.
The trial represents the world’s first pivotal study of an mRNA vaccine designed specifically for a potential influenza pandemic. mRNA technology has a significant advantage over traditional egg-based manufacturing: it can be updated quickly when a virus mutates, and production can scale faster because it doesn’t depend on millions of fertilized chicken eggs. If approved, this vaccine could dramatically shorten the gap between identifying a pandemic strain and getting shots into arms.
Why You Can’t Get Vaccinated Right Now
Even though an approved vaccine exists, there’s no public vaccination campaign because H5N1 hasn’t started spreading efficiently between people. The virus has infected dairy cattle herds and caused sporadic human cases, mostly among farmworkers with direct animal contact, but sustained human-to-human transmission hasn’t occurred. Launching mass vaccination before that happens would mean using limited doses against a virus that may never reach the general population, while potentially diverting resources from seasonal flu vaccination.
If H5N1 did begin spreading between people, the government’s plan is to deploy stockpiled doses to high-risk groups first while ramping up manufacturing. The 4.8 million doses currently planned would cover a fraction of the U.S. population, so production would need to scale rapidly, which is one reason mRNA technology is being pursued as a faster alternative to egg-based manufacturing.
Vaccines for Poultry and Livestock
The situation is different for animals. The USDA does not currently vaccinate commercial poultry against highly pathogenic avian influenza in the United States. The standing policy relies on surveillance, quarantine, and depopulation (culling all affected and exposed birds) to contain outbreaks. There is no approved treatment for highly pathogenic bird flu in poultry.
This approach exists partly because of trade concerns. Countries that vaccinate poultry can have difficulty proving their flocks are truly free of the virus, since vaccinated birds may carry and spread H5N1 without showing symptoms. That makes trading partners reluctant to import poultry products. Some other countries do vaccinate their flocks, but the U.S. has so far prioritized the “stamp out” strategy. No vaccine is currently approved for use in cattle either, despite the ongoing spread of H5N1 through dairy herds.
Global Preparedness Efforts
The World Health Organization maintains an updated list of candidate vaccine viruses for pandemic preparedness, covering not just H5N1 but multiple avian and variant influenza subtypes including H5 non-H5N1, H7N9, H9N2, and H10. These candidate viruses are shared with manufacturers worldwide so they can begin developing matched vaccines quickly if a pandemic strain emerges. For the 2026-2027 season, H5N1 sits at the top of that list, reflecting the current level of global concern about the virus.
Multiple countries hold their own stockpiles and have agreements with vaccine makers for priority access during a pandemic. The challenge remains speed: producing enough doses for billions of people takes months with conventional manufacturing, which is why investments in mRNA and cell-based vaccine platforms are accelerating. The goal is to compress the timeline from viral emergence to population-level protection from many months down to weeks.